The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.
Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been ...
The most consistent anomalies are nasal hypoplasia and stippling of vertebrae or bony epiphyses. Management of pregnant patients on anticoagulation is challenging. Current guidelines suggest the use ...
"Our goal is to provide a safer and superior blood thinner option for patients who rely on chronic anticoagulation but are underserved by current treatments. Warfarin, the first VKA anticoagulant ...
(Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been recognized as the 2024 "Anticoagulation Therapy Company of ...
1 Despite strong evidence that treatment with direct oral anticoagulants prevents first ever stroke in people with atrial fibrillation, when to commence anticoagulation in patients with acute ...
The Johns Hopkins Anticoagulation Management Service is a collaboration between the Department of Hematology and Department of Pharmacy. The service is staffed by expert physician and pharmacists who ...